


FIG. 1A




FIG. 1B




FIG. 1C




FIG. 2




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 4




FIG. 5




FIG. 6A




FIG. 6B




FIG. 7




FIG. 8




FIG. 9




FIG. 10




FIG. 11




FIG. 12




FIG. 13



IFN ELISpot Pre-treatment Pt 3
50
45
40
35
30
25
20
15
10
5
0
no antigen
HBc
HBs
FLL
GLS
ILS
SFC

FIG. 14



FLL
GLS
ILS

FIG. 15




FIG. 16




FIG. 17




FIG. 18




FIG. 19




FIG. 20




FIG. 21



NY-ESO-1
SSX-2
Melan A
MAGE-A4

FIG. 22





100000
90000
80000
70000
60000
50000
40000
30000
20000
10000
0
Pre
Day 14
Day 30
Day 60
NY-ESO-1
SSX-2
Melan A
MAGE A4

FIG. 23



Before



6 Mo. Post T Cell Therapy

FIG. 24




FIG. 25




T Cell Therapy
Remission
Rituxan + CHOP
Retreatment
18-24 months
Time post treatment

FIG. 26


T Cells Subdominant (TS)
96.3 %
CD25
CD4



Treg Dominant (TD)
92.4 %
CD25
CD4

FIG. 27



Clinical Score Day 20-45 Post Induction
Average Clinical Score
3.5
3
2.5
2
1.5
1
0.5
0
1
2
3
4
5
6
7
8
9
PBS
Treg D
TS
Treg D + TS

FIG. 28





Incidence of Arthritis 20-45 Days Post Induction
Incidence of Arthritis %
90
80
70
60
50
40
30
20
10
0
1
2
3
4
5
6
7
8
9
PBS
Treg D
TS
Treg D + TS

FIG. 29




Normal

FIG. 30A



Immunized with human proteoglycan

FIG. 30B



Treated with T cells

FIG. 30C




FIG. 31